Evidence-based Assessment of Adherence to Medical Treatments in Pediatric Psychology

Alexandra L. Quittner,1 PhD, Avani C. Modi,2 PhD, Kathleen L. Lemanek,3 PhD, Carolyn E. Ievers-Landis,4 PhD and Michael A. Rapoff,5 PhD

1Department of Psychology, University of Miami, 2Department of Pediatrics, Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati School of Medicine, 3Department of Clinical Pediatrics, Columbus Children’s Hospital, Ohio State University College of Medicine, 4Division of Behavioral Pediatrics and Psychology, Rainbow Babies and Children’s Hospital, Case Western Reserve University School of Medicine and 5Division of Behavioral Pediatrics, University of Kansas School of Medicine

Objectives Adherence to medical regimens for children and adolescents with chronic conditions is generally below 50% and is considered the single, greatest cause of treatment failure. As the prevalence of chronic illnesses in pediatric populations increases and awareness of the negative consequences of poor adherence become clearer, the need for reliable and valid measures of adherence has grown. Methods This review evaluated empirical evidence for 18 measures utilizing three assessment methods: (a) self-report or structured interviews, (b) daily diary methods, and (c) electronic monitors. Results Ten measures met the “well-established” evidence-based (EBA) criteria. Conclusions Several recommendations for improving adherence assessment were made. In particular, consideration should be given to the use of innovative technologies that provide a window into the “real time” behaviors of patients and families. Providing written treatment plans, identifying barriers to good adherence, and examining racial and ethnic differences in attitudes, beliefs and behaviors affecting adherence were strongly recommended.

Key words adherence; diary methods; electronic monitors; empirically-supported; measurement.

Historically, the field of psychology has made significant and lasting contributions to the development of reliable and valid measures, with recent efforts focused on measures that are directly linked to interventions and treatment outcomes (Quittner, 2000; Sechrest, McKnight, & McKnight, 1996). In fact, instrument development and assessment is one of psychology’s greatest strengths. Thus, this Special Series logically extends prior reviews on evidence-based treatment to critical evaluations of assessment measures (Mash & Hunsley, 2005; Nelson-Gray, 2003). The purpose of this article is to provide an evidence-based review of measures that assess adherence to medical regimens for children and adolescents with chronic conditions, with an emphasis on their utility in research and clinical contexts.

Measuring Adherence Behaviors: Definition and Importance

There is little controversy about the definition of adherence. Over the past 30 years, adherence has been defined as: “The extent to which a person’s behavior (in terms of taking medications, following diets, or executing lifestyle changes) coincides with medical or health advice” (Haynes, 1979; pp. 1–2). The complicating issue is determining precisely what that “medical advice” is. Once the prescription has been determined, including dose, frequency, duration (if applicable), and timing, a rate of adherence can be calculated.

The assessment and treatment of adherence has become central to improving health outcomes as the prevalence of chronic conditions increases and as medical
treatments become more complex. Advances in health care, including public health initiatives, vaccines, and better treatments for previously fatal conditions, such as leukemia and cystic fibrosis (CF) are partly responsible for this increase. Further, environmental pollutants and lifestyle issues (e.g., obesity) have led to dramatic increases in diseases, such as asthma and type 2 diabetes (DeAngelis & Zylke, 2006). Prevalence rates based on two large survey studies have reported similar estimates of children with chronic conditions—12.8% or approximately 9.3 million children (Newacheck & Hallon, 2000; van Dyck, Kogan, McPherson, Weissman, & Newacheck, 2004). In this context, adherence to medical treatments becomes a central issue in these children’s and families’ lives: “an endless cycle of medications, treatments, procedures, and medical visits” (Anderson & Collier, 1994; p. 394).

Rates of adherence for children with chronic illnesses vary depending on the disease, complexity of the regimen, and measures that are used (DiMatteo, Giordani, Lepper, & Croghan, 2002; Quittner, Espelage, levers-Landis, & Drotar, 2000b; Rapoff, 1999). However, there is consensus across studies that rates of adherence are generally below 50% (Dunbar-Jacob & Mortimer-Stephens, 2001; La Greca & Bearman, 2003; Rapoff, 1999). Adherence is often better for simple behaviors, such as pill taking, but is substantially lower for more complex behaviors, such as dietary modifications, glucose monitoring, and nebulized medications (DiMatteo, 2004; Modi et al., 2006; Quittner et al., 2000a; Wysocki et al., 2000).

The consequences of poor adherence are extremely serious. Failure to take medications as prescribed can result in drug resistance, drug reactions, increased morbidity and mortality, and reduced quality of life (Dew et al., 2001; Kelly & Kalichman, 2002). Nonadherence has been estimated to compromise the health outcomes of pediatric treatments by an average of 33% and by as much as 71% (DiMatteo et al., 2002). Poor adherence also affects health care provider behavior, potentially leading to increased dosages or discontinuation of medication believed to be ineffective (DiMatteo et al., 2002). Data from clinical trials evaluating new treatments and effective doses can also be compromised by inconsistent or poor adherence to the treatment (Christensen, 2004). Finally, an estimate of health care dollars wasted due to poor adherence is approximately 300 billion dollars annually (DiMatteo, 2004). In sum, poor adherence has been cited as the single greatest cause of treatment failure.

Challenges of Measuring Adherence Behaviors

There are a number of unique challenges faced by researchers and clinicians seeking to assess adherence behaviors. These challenges include, but are not limited to: (a) use of different time scales from 24 h recall to global self-reports over 1–3 months, making it difficult to combine data across measures; (b) advances in medical treatments which are progressing more rapidly than our ability to develop reliable and valid instruments; (c) data obtained from multiple respondents (e.g., patient, parent) without certainty about which respondent will provide the most accurate data; (d) determination of the prescription; and (e) rapidly changing treatments for patients.

One of the most difficult problems, which has largely been ignored, is determining exactly what the physician has prescribed so that a calculation of adherence is possible (Modi et al., 2006; Quittner et al., 2000b). Often in complex chronic conditions, such as diabetes, HIV-AIDS and CF, several treatments and dietary modifications must be adhered to each day. Extensive reviews of patient charts in pediatric pulmonary clinics, for example, indicate that little reliable or consistent information can be gathered from these charts on the treatment regimen (Quittner et al., 2000a).

Further complicating this process are the rapidly changing treatments for these patients, which may require changes to the regimen (e.g., intensive insulin regimens for diabetes; use of insulin pump) and greater patient responsibility (e.g., home intravenous antibiotics for CF). If physicians do not provide a written treatment plan to children and families, it can be very difficult to assess whether dosages, duration of treatment, or changes to the daily regimen were understood by the patient and family (Modi & Quittner, 2006a). Although this may seem like a basic step in assessing and improving adherence, surprisingly, few written treatment plans are provided to families, even for the most complex medical regimens [see the Prescribed Treatment Plan; (Modi & Quittner, 2006a; Modi et al., 2006) for an exception].

Measurement Review

Selection of Measures

As described in the Introductory article (Cohen et al., in press), members of Division 54 formed review groups in eight content domains. This group of reviewers comprised the American Psychological Association (APA)
Division 54 Evidence-Based Assessment (EBA) Task Force. First members of the Task Force were asked to generate a list of existing measures in their respective domains. The Adherence Workgroup identified measures of adherence that included self-report questionnaires and interviews, daily diaries, and electronic monitors. In 2003, Division 54 posted these measures on the listserv to assess their rate of endorsement; however, too few Division 54 members were using these measures to use this as the selection criterion. Instead, given that these measures were relatively new (most developed in the last 10 years), we reviewed all of the measures generated by the Adherence Workgroup for which we could find sufficient published psychometric data or information from the author/s. In addition, we conducted a literature search and added a few measures suggested by members of the listserv.

There are several different methods of assessing adherence behaviors: (a) self-report questionnaires and structured interviews, (b) diary measures, (c) electronic monitors, (d) prescription refill histories, and (e) biochemical assays [see (Drotar, 2000; Quittner et al., 2000b; Rapoff, 1999) for reviews]. We did not include biological assays because their measurement properties seemed beyond the scope of this review and we did not include pharmacy refill indices because they are often designed and accessed through pharmacy databases, which are not currently standardized. Each method has different strengths and weaknesses in terms of reliability, validity, and cost which were included in this review. A total of 18 measures were included (see Appendix A).

We used the EBA criteria that have been endorsed by APA (Chambless & Ollendick, 2001) to review the adherence measures. The three evidence-based categories are as follows: (a) well-established assessment (e.g., at least two research teams have published sufficient information evaluating the measure and establishing its strong psychometric properties); (b) approaching well-established assessment (e.g., measures have been published in at least two articles indicating reasonable or vague psychometric properties); and (c) promising assessment (e.g., measures have been published in at least one peer-reviewed article indicating reasonable or vague psychometric properties). Similar to the criteria for evidence-based interventions in the literature on psychological treatments, a measure must have been utilized by more than one investigative team to meet the criteria for “well-established.”

**Self-report Questionnaires and Structured Interviews**

The use of patient or parent self-report is the most common method of assessing adherence. Both self-report measures and structured interviews have been developed to measure adherence for a variety of pediatric chronic conditions, including asthma, diabetes, HIV/AIDS, and CF. Self-report measures have a number of strengths. They are inexpensive, comprehensive, and available for multiple informants (patients, parents, healthcare providers). Structured interviews also allow for follow-up questions which can provide important information about patient perceptions of the regimen and specific barriers. However, weaknesses include the tendency to overestimate adherence, problems with accurate recall, assessment of global perceptions rather than frequencies of behavior (e.g., “Did you eat more calories today?” vs. “How many snacks did you eat today?”), and the difficulty of using them with younger children (8 years and below). Finally, for complex regimens, treatments may be shared or supervised by several caregivers (e.g., parents, grandparents, school staff), from whom the data must also be collected.

Eleven self-report or structured interview measures of adherence were reviewed across six chronic conditions: diabetes, transplantation, CF, asthma, HIV/AIDS, and spina bifida. Several of these measures were designed to be completed by both parents and adolescents. The largest number of self-report measures focused on diabetes (three of the nine), including the Self-Care Adherence Interview (SCAI) (Hanson et al., 1989), Self-Care Inventory (SCI) (La Greca, Swales, Klem, & Madigan, 1988), and the Diabetes Regimen Adherence Questionnaire (DRAQ) (Brownlee-Duffeck et al., 1987) (Table I). In addition, the Disease Management Interview is being adapted for diabetes (Johnson & Quittner, 2001) but has not appeared in a peer-reviewed publication. All of these measures reported good psychometric properties in terms of either internal consistency or stability coefficients, and most had validity data that demonstrated a significant association between adherence and better glycemic control. The SCI and DRAQ adherence scores also converged with other measures—either the 24 h recall diary (Johnson, Silverstein, Rosenbloom, Carter, & Cunningham, 1986) or an assessment of health beliefs and social problem-solving skills (Bond, Aiken, & Somerville, 1992; Thomas, Peterson, & Goldstein, 1997). Both of the SCI and DRAQ measures were categorized as “well-established” and the SCAI was categorized as “approaching well-established.”
<table>
<thead>
<tr>
<th>Measure/Authors</th>
<th>EBA classification</th>
<th>Number of items/Respondent</th>
<th>Internal consistency</th>
<th>Test–retest reliability</th>
<th>Interrater reliability</th>
<th>Validity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diabetes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Self-Care Adherence Interview (SCAI) (Hanson et al., 1989, 1992, 1996)</td>
<td>Approaching well-established interview/Parents and adolescents (10–20 years)</td>
<td>15-item semi-structured interview/Parents and adolescents (10–20 years)</td>
<td>Not assessed</td>
<td>3-month $r = .70$ 6-month $r = .68–.70$ 1-year $r = .71$</td>
<td>$r = .95–.98$</td>
<td>Correlations between the SCI and glycemic control ranged from $-0.20$ to $-0.28$ in different samples. Good correlations reported between 24-hr recall and SCI. Higher levels of self care (SCI) reportedly associated with better metabolic control.</td>
</tr>
<tr>
<td>Self-Care Inventory (SCI) (Davis et al., 2001; Delamater et al., 1997; Greco et al., 1990; La Greca et al., 1988; Wysocki et al., 2000)</td>
<td>Well-established</td>
<td>14-items/Parents and adolescents</td>
<td>$\alpha = .76$ adolescent; $\alpha = .87$ parent</td>
<td>2-week $r = .77$</td>
<td>Not assessed</td>
<td>Good correlations with health beliefs ($r's = .29–.33$) and some social problem-solving skills ($r's = .43–.64$)</td>
</tr>
<tr>
<td>Diabetes Regimen Adherence Questionnaire (DRAQ) (Bond et al., 1992; Brownlee-Duffeck et al., 1987; Thomas et al., 1997)</td>
<td>Well-established</td>
<td>15-items; adolescents (8–17 years)</td>
<td>Total $\alpha = .78–.80$</td>
<td>Not assessed</td>
<td>Not assessed</td>
<td>Good correlations with health beliefs ($r's = .29–.33$) and some social problem-solving skills ($r's = .43–.64$)</td>
</tr>
<tr>
<td><strong>Transplant</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Behavioral Affective and Somatic Experiences (BASES): Compliance Scale (Parent version) (Phipps et al., 1994)</td>
<td>Approaching well-established</td>
<td>38-items; compliance scale 8-items/Parents of children who have undergone transplantation</td>
<td>Total $\alpha = .77$</td>
<td>Not assessed</td>
<td>Nurse-Parent Agreement: $r = .56$ median correlation</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Self-Regulation of Medication Adherence Battery (SRMAAB) (Tucker et al., 2001)</td>
<td>Promising</td>
<td>10-items/Patients who have undergone renal transplants (6–20 years old)</td>
<td>Not assessed</td>
<td>Not assessed</td>
<td>Not assessed</td>
<td>Sensitive to cultural differences in adherence between African-American and Caucasian patients.</td>
</tr>
<tr>
<td><strong>Cystic fibrosis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease Management Interview-CF (DMI-CF) (formerly Treatment Adherence Questionnaire) (Quittner et al., 2000a)</td>
<td>Well-established</td>
<td>51 items/Parents and children over 10 years</td>
<td>Not assessed</td>
<td>$r's = .62$ to .73 (adolescent reports) $r's = .76$ to .88 (parent reports)</td>
<td>Parent-Teen Agreement: $r = .55$ nebulated meds $r = .78$ CPT Parent-Child Agreement: $r = .69$ nebulated meds $r = .88$ CPT</td>
<td>Not assessed</td>
</tr>
</tbody>
</table>
Two measures of adherence for patients who have undergone a solid organ transplant were reviewed. One measure, the Behavioral Affective and Somatic Experiences-Compliance Scale (BASES) (Phipps, Hinds, Channell, & Bell, 1994) reported good internal consistency coefficients and reasonable agreement between parents and nurses, but did not report any validity data. Two other empirical articles using the BASES have been published, but they were written by the same investigatory group and thus, this measure fell into the “approaching well-established” category. The other measure, the Self-Regulation Medication Adherence Battery (SRMAAB) (Tucker et al., 2001) did not report any psychometric information, but found convergence between these adherence scales and cyclosporine levels. Furthermore, this measure was sensitive to the cultural differences between African-American and Caucasian transplant patients, with unique predictors of adherence.

<table>
<thead>
<tr>
<th>Measure/Authors</th>
<th>EBA classification</th>
<th>Number of items/Respondent</th>
<th>Internal consistency</th>
<th>Test–retest reliability</th>
<th>Interrater reliability</th>
<th>Validity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment Adherence Rating Scale (TARS; DeLambo et al., 2004)</td>
<td>Promising</td>
<td>16 items/Parents and children/adolescents</td>
<td>Airway Clearance/ $r's = .42$ to $.57$ among informants</td>
<td>Not assessed</td>
<td>Not assessed</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Asthma</td>
<td>Approaching well-established</td>
<td>Semi-structured interview; Parents of children with asthma with children (11–17 years old)</td>
<td>Total $\alpha = .84$</td>
<td>Not assessed</td>
<td>Intraclass correlations ranged from 0.67–0.93</td>
<td>Adherence scores significantly related to functional impairment/morbidity ($r = -0.39$), parent knowledge ($r = 0.36$), and child self-efficacy ($r = 0.36$). Adequate convergence with MDIlog data ($r = .29$)</td>
</tr>
<tr>
<td>Disease Management Interview–Asthma (Modi &amp; Quittner, 2006a)</td>
<td>Promising</td>
<td>28 items/Parents and children $&gt;10$ years.</td>
<td>Not assessed</td>
<td>Not assessed</td>
<td>Parent-child agreement: $r = .63$</td>
<td>Child self-report of adherence associated with number of barriers to adherence ($r = 0.46$)</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>Pediatric AIDS</td>
<td>Promising</td>
<td>2 Interview-administered modules/Parents and children (0–17 years old)</td>
<td>Not assessed</td>
<td>Not assessed</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Spina Bifida</td>
<td>Parent Report of Medical Adherence in Spina Bifida Scale (PROMASB) (Holmbeck et al., 1998)</td>
<td>Approaching well-established</td>
<td>39 items/Parents of children with spina bifida</td>
<td>$\alpha &gt; .65$ for 13 of 15 scales</td>
<td>Not assessed</td>
<td>Mother–father agreement: $r = 0.39$</td>
</tr>
</tbody>
</table>
identified for each group. Thus, this measure was categorized as “promising.”

Two measures of adherence for CF were reviewed, the Disease Management Interview-CF (DMI-CF), originally titled the Treatment Adherence Questionnaire (Quittner et al., 2000b) and the Treatment Adherence Regimen Scale [TARS; (DeLambo, Ievers-Landis, Drotar, & Quittner, 2004)]. These measures have both parent and adolescent versions. Strong psychometric characteristics have been reported for the DMI-CF, including test–retest reliability, parent-adolescent agreement, and associations between adherence and knowledge of the treatment regimen. The DMI-CF has appeared in two independent peer-reviewed publications and thus is considered a “well-established” measure. The TARS was also found to have good psychometric properties for a majority of scales; however, it has only been utilized in one published study and is therefore considered “promising.”

Two measures of adherence for children with asthma were reviewed: the Disease Management Interview-Asthma (DMI-Asthma) (Modi & Quittner, 2006a) and the Family Asthma Management System (FAMSS) (Klinnert, McQuaid, & Gavin, 1997). The DMI-Asthma interview was developed for children with asthma ages 10 and older and their parents. This is a newly developed measure and little psychometric information is available. Good parent–child agreement was demonstrated and children’s self-reported adherence was correlated with the number of barriers to adherence they reported. The DMI-Asthma was categorized as a “promising” measure. The FAMSS is a semi-structured interview conducted with both children with asthma ages 11–17 and their parents. Psychometric data on internal consistency, interrater agreement, and convergent validity with child self-efficacy, knowledge, and electronic data are all strong. Note that training and reliability for coders must be established prior to use. Information on the FAMSS has been published by two research teams and thus is a “well-established” measure.

One measure of adherence was found for pediatric HIV-AIDS, the Pediatric AIDS Clinical Trials Group (PACTG): Adherence Modules (Farley et al., 2003). The PACTG has two modules that assess adherence which are administered by interview. No psychometric data have been published to date; however, the measure has been used in three published studies, with one reporting significant associations between adherence and virological response and two finding no association. Further psychometric work is needed on this measure, placing it in the “promising” category.

One measure of adherence for children with spina bifida was reviewed, the Parent Report of Medical Adherence in Spina Bifida Scale (PROMASB) (Holmbeck et al., 1998). This is a parent self-report measure which has shown generally good internal consistency, good agreement between mothers and fathers, and high interrater agreement. Validity data have not yet been published. This measure is classified as “approaching well-established.”

### Daily Diary Methods

Diary measures can take several forms, including written logs, hand-held computers (PDAs) with time-sensitive prompts, and phone diaries completed directly with the respondent. Prior studies indicate that compliance with written logs is extremely poor and they are often completed just prior to their return, rather than on a daily basis (Johnson, 1993). Given that patients have difficulty adhering to their medical regimens, it is not surprising that they also have difficulty tracking their behaviors on diary cards. In contrast, modern diary methods, such as ecological momentary assessment [EMA; (Csikszentmihalyi & Larson, 1987)] and day reconstruction methods [DRM; (Kahneman, Krueger, Schkade, Schwarz, & Stone, 2004)] which assess daily activity patterns, hold considerable promise for measuring adherence because they obviate the most serious weaknesses of questionnaire/interview data—problems with memory and recall (Johnson, 1993; Modi & Quittner, 2006b; Quittner et al., 2000b).

The measurement of daily activities via phone or PDA has several advantages over self-report methods. First, data is collected in real-time or within a short, 24-hr period so that actual behaviors, rather than global estimates are obtained. Second, because data is collected in real-time, there is less memory decay and less potential for social desirability biases to affect reports. For example as adolescents are tracked through a 24-hr period by phone, it is difficult for them to insert an activity that did not occur; thus, the absence of time devoted to medical treatments indicates poor adherence. Furthermore, Modi and Quittner (2006b) reported that data from the Daily Phone Diary more closely converged with objective electronic monitors than self-report questionnaires. Diary methods also facilitate identification of barriers to adherence because of the temporal nature of the data. Finally, phone diaries can be unobtrusive measures of adherence because all activities over the previous 24-hr are recorded and patients and families are typically unaware that treatment activities are the focus of the
These monitors are now available to record and store the development of automated measures of adherence. Technological advances in microprocessors have led to Electronic Monitors a "well-established" measure. Sets that require more sophisticated analytic procedures (Larson & Delespaul 1992; Modi & Quittner, 2006b).

Two cued-recall diary measures have been developed to assess adherence, one for children with diabetes and one which has been applied to a variety of chronic illnesses (e.g., CF, asthma, HIV-AIDS) (Table II). The 24 hr Recall (Johnson et al., 1986) measure is a phone-based diary that has been used for two decades to assess adherence in children and adolescents with diabetes. Strong stability coefficients, good parent–child agreement, and associations between adherence and glycemic control have been reported. A recent article applying this measure to HIV-AIDS (Marhefka, Tepper, Farley, Sleasman, & Mellins, 2006) was published by a second, independent group, making it a "well-established" measure.

The second cued-recall measure, the Daily Phone Diary (the DPD) (Quittner & Opipari, 1994), was developed initially to assess adherence behaviors (as well as family activities) in children and adolescents with CF. The DPD measure is available for children and adolescents with CF and adolescents with CF. Good stability over a 3-week period, high levels of interrater agreement, and strong convergence between the DPD and electronic monitors have been reported. The DPD was recently adapted for parents of children with asthma (Modi & Quittner, 2006b) and HIV-AIDS (Wiener et al., 2004), with modest-to-strong convergence found between diary-measured adherence and the MDILog (an electronic monitor for metered-dose inhalers), and significant associations found between DPD-reported adherence and viral loads in children with HIV. Published articles are from two independent research groups making this a "well-established" measure.

**Electronic Monitors**

Technological advances in microprocessors have led to the development of automated measures of adherence. These monitors are now available to record and store information on the date and time of tablet or liquid medication removal from standard vials, removal of pills from blister packages, actuation of metered-dose inhalers, blood glucose test results, and patient diary notations on adherence or other clinical events, such as pain levels. These monitors can store information in real-time from several months to 3 years and can be downloaded into data files for analysis. This is one of the most exciting developments in adherence measurement, with some even calling electronic monitors the “new gold standard” (Cramer, 1995; Rapoff, 1999).

As with other measures of adherence, electronic monitors have advantages and disadvantages. In terms of advantages, electronic monitors provide a continuous and long-term measure of medication adherence in real-time, which is not available with any other measure. Monitors can also reveal a spectrum of adherence problems, including: (a) underdosing (the most common dosing error); (b) overdosing (which can contribute to toxic effects); (c) delayed dosing (dosing that exceeds recommended intervals, reducing therapeutic coverage); (d) drug “holidays” (omitting doses for several days without authorization); and (e) “white-coat” adherence or giving the appearance of adequate adherence by “dumping” medications or taking them consistently several days before clinic visits [see (Rapoff, 1999; Riekert & Rand, 2002) for reviews].

Despite these advantages, electronic monitors are a relatively new phenomenon and have several disadvantages. First, although the monitor records precisely when a pill bottle is opened, what they measure is “presumptive” dosing—an assumption that patients ingest what they dispense. However, this is a problem with all of the methods of measurement we have reviewed—only biochemical assays are able to confirm, through blood levels, that the drug has actually been taken. Monitors can also underestimate adherence if patients take out several doses at once to carry with them when they are away from home or to load pill reminder boxes.

Electronic monitors, like any mechanical device, can malfunction. They may record events that did not occur, fail to record events that did occur, or simply stop working due to battery failures. Missing data due to device failure has ranged from 0% to 24% (Riekert & Rand, 2002). Although mechanical failures are typically associated with the first or second prototypes of a device, malfunctions can also occur because of patient behavior (e.g., taking the device apart, cleaning it).
is also problematic because of the relatively high costs of purchasing the monitors, communicators, and proprietary software. For example, MEMS caps cost $130 per cap and families often request three or more caps. Practical issues, such as portability and improper fit between the medication and device may also reduce their utility. Unfortunately, development of monitoring devices has lagged behind development of new medications. For example, nebulized medications have been recently reformulated as dry powder. Finally, in order to

| Table II. Summary of Reliability and Validity for Diary Measures of Adherence |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Measure         | EBA classification | Respondent          | Test-retest reliability | Interrater reliability | Validity |
| 24-hr Recall    | Well-established   | Parents and children with diabetes (6–19 years old) | Diabetic: Injection regularly: .06–.35 Injection interval: .38–.49 Injection-meal (IM) timing: .58–.71 Regularity IM timing: .24–.31 Exercise frequency: .40–.63 Exercise duration: .42–.74 Exercise type: .37–.48 Eating frequency: .63–.77 Calories consumed: .67–.74 Calories from carbs (%): .45–.61 Calories from fat (%): .51–.63 Concentrated sweets: .51–.53 Glucose testing: .72–.76 Intraclass correlations-HIV: Frequency: .55 Interval: .71 Dietary: .68 | Parent-child agreement: Injection regularly: .62–.74 Injection interval: .72–.87 IM timing: .64–.79 Regularity IM timing: .27–.40 Exercise frequency: .65–.75 Exercise duration: .57–.89 Exercise type: .64–.76 Eating frequency: .65–.78 Calories consumed: .66–.76 Calories from carbs (%): .71–.76 Calories from fat (%): .73–.77 Concentrated sweets: .59–.83 Glucose testing: .91–.94 | Better adherence was associated with better metabolic control in structural equation modeling, but variance accounted for by adherence was small. In an HIV sample, 24-h recall was negatively correlated with viral load ($r$’s = −.33 and −.35) but not average viral load. Specificity and sensitivity with viral load ($>$400) ranged from 21–37% and 63–83%, respectively for the frequency and interval scales. |
| Daily Phone Diary (Modi & Quittner, 2006b; Quittner & Opipari, 1994; Wiener et al., 2004) | Well-established | Parents of children with chronic illnesses / Adolescents with chronic illnesses | Stability coefficients over a 3-week period. $r$’s = .61–.71 | High levels of interrater reliability >90% | Strong convergence (77–80%) was found for daily routines between the DPD and Self Observation Report Technique. Modest to strong convergence ($r$’s = 0.43–0.94) between the DPD and electronic monitors across CF and asthma. Adolescents with HIV who reported perfect adherence (DPD) were 5 more likely to have a low viral load. DPD protease inhibitor adherence was negatively correlated with viral load (Spearman $r$ = −0.48). |
download data from the monitors, they have to be retrieved and in some cases, patients have lost the monitors or have not returned them.

Reliability and Validity Issues
Traditional reliability estimates, such as internal consistency and test–retest reliability, are less relevant for electronic monitors than other methods of assessment. Accuracy is critically important and bench studies in which monitors are triggered by investigators at predetermined times and compared to written records of device actuations are critical for ensuring that monitors are functioning as designed. Periodic calibration and testing is also important when using these devices in an ongoing study or clinical trial.

Electronic monitors have been considered more accurate than other measures because they are “objective” and typically reveal lower rates of adherence when compared to patient or parent self-reports, physician estimates, and pharmacy refill records (Rapoff, 1999; Rieker & Rand, 2002). This claim of greater accuracy rests on the assumption that electronic monitors are the “gold standard” of adherence, an issue which has been hotly debated (DiMatteo, 2004; Rieker & Rand, 2002). Although we have thoroughly reviewed electronic monitoring measures, it is difficult to categorize them using the EBA criteria. Thus, we have placed them all in the “well-established” category if they have been shown to be accurate and converge with at least one other “well-established” measure (Table III).

Medication Management System (MEMS)
The MEMS bottle cap records the date and time of pill bottle opening. MEMS caps have been used to measure medication-taking in pediatric patients with HIV-AIDS, CF, β-thalassaemia, and tuberculosis (TB) (Blowey et al., 1997; Farley et al., 2003; Modi et al., 2006; Olivieri et al., Starr et al., 1999). It has been shown to be highly accurate in benchmarking studies. Convergent and predictive validity have also been established. The MEMS demonstrated good convergence with pharmacy refill and daily diary data for children with CF (Modi et al., 2006), as well as urine assays for patients with TB (Starr et al., 1999). MEMS data also predicted viral load in children with HIV-AIDS (Farley et al., 2003).

Metered Dose Inhaler (MDI) Monitors (MDILog, Nebulizer Chronolog, Doser CT)
For patients with asthma and CF, several medications are administered via MDI, including β-agonists and steroids. Older electronic monitors, such as the Doser CT, recorded the date and number of puffs taken via the MDI. Accuracy of the Doser in bench studies was 94.3%; however, this device does not record the time of each actuation and data cannot be downloaded to the computer. Failure rate in one study was significant (21%) (Bender et al., 2000) and because the Doser uses an older technology, it is no longer available. The Nebulizer Chronolog is also an older electronic monitoring device that has been used to record asthma medications. Three studies of pediatric patients with asthma were located that used the Nebulizer Chronolog, which all showed that adherence was considerably lower as measured by the Chronolog than patient reports (Chemlilk & Doughty, 1994; Gibson et al., 1995; Milgrom et al., 1996). For example, Bender and colleagues (1998) reported that complete use of β-agonists was 30% by patient report versus 12.7% with the Chronolog. Interestingly, inflated patient reports of adherence were correlated with lower parent education and less affective responsiveness in the family. Both the Doser and Nebulizer Chronolog are only briefly described in this review to provide relevant history regarding the use of electronic monitors; however, they were not included in the Appendices because they are no longer used for research or clinical purposes.

The newer MDILog was benchmarked in 2001 in a comparison of three MDILog devices. This device can identify errors in administration of the medication with an impressive rate of accuracy: actuation accuracy was 97–100%, inhalation accuracy was 86–95%, and late inhalations and multiple actuation accuracy was 97–99% (Apter et al., 2001). Importantly for children and adolescents, no artifactual recordings were observed when MDILogs were carried in bookbags over 3 days (Apter et al., 2001). The newest version of the MDILog is more accurate and reliable than previous versions. Rates of adherence on the MDILog correlated with other measures of adherence, such as the Daily Phone Diary for children with CF and asthma (Modi et al., 2006).

Halolite Nebulizer Monitor
The Halolite™ is an adaptive aerosol delivery (AAD™) system that only releases aerosol medication when inhalation is detected. This shortens the treatment time for nebulized medications by 40%. The Halolite™ records the date, time, and duration of each nebulized treatment. In addition, any form of nebulized medication can be used in the Halolite™ (e.g., inhaled tobramycin, dornase alpha, bronchodilators), which is an advantage over newer nebulizers that can only be used with specific medications. Data from two studies on the Halolite™ suggest that it converges well with the Daily
<table>
<thead>
<tr>
<th>Reference</th>
<th>Sample/Regimen</th>
<th>Comparison</th>
<th>Results</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEMS trackcaps</td>
<td>n = 19 adolescents (12.5–17.9 years), post-renal transplant/cyclosporine</td>
<td>MEMS-4 compared to drug assays (n = 14) and physician or nurse &amp; patient estimates</td>
<td>2 of 4 patients identified as nonadherent by MEMS, had low cyclosporine levels (&lt;50 ng/ml). Physician or nurse &amp; patient estimates correctly identified 2 of 4 nonadherent patients</td>
<td>Mean adherence rate by MEMS = 91% (range 64% to 100%)</td>
</tr>
<tr>
<td>(Blowey et al., 1997)</td>
<td>n = 14 (12 months to 14 years) with antiretroviral medications</td>
<td>MEMS compared to pharmacy refill rates, caregiver self-report, physician/nurse assessment, and appointment keeping</td>
<td>Sensitivity and specificity for predicting viral load was best for MEMS vs. other measures; combining MEMS and pharmacy refill rates resulted in highest sensitivity and specificity for predicting viral load; MEMS significantly correlated with pharmacy refill rates and physician/nurse assessments but not caregiver report or appointment keeping</td>
<td>Adherence cutoff score of 80% derived from MEMS data predicted viral load (14 of 15 children with MEMS adherence rate &gt;80% had an acceptable viral load). Adherence rates by MEMS ranged from 12.7 to 97.9% (median = 81.4%)</td>
</tr>
<tr>
<td>(Farley et al., 2003)</td>
<td>n = 26 (21 months to 12.5 years) with antiretroviral medications</td>
<td>MEMS vs. pill counts, urine assay, clinic attendance, and self-report</td>
<td>Mean adherence by MEMS was 66 vs. 91% pill counts, 79% assay, and 83% clinic attendance; 65% of self-reports were inconsistent with MEMS data, generally overestimating adherence</td>
<td>Some patients did not bring MEMS device to clinic, resulting in incomplete data; metabolites of isoniazid are only present in urine for 24 hr after ingestion</td>
</tr>
<tr>
<td>(Starr et al., 1999)</td>
<td>n = 21 adolescents with positive TB tests/isoniazid oral medication</td>
<td>MEMS vs. self-report, pharmacy refill history, and daily phone diaries</td>
<td>A significant difference was found between parent-reported adherence and more objective measures, with parents reporting higher adherence rates compared to pharmacy refill history, diary data, and electronic monitoring (p’s &lt; .05)</td>
<td>Parent report of adherence was 80% compared to 30–40% for pharmacy refill, diary data, and electronic monitoring</td>
</tr>
<tr>
<td>(Modi et al., 2006)</td>
<td>n = 37 children with cystic fibrosis (6–13 years)</td>
<td>MEMS vs. pill counts and patient diaries</td>
<td>Mean adherence by MEMS was 88.7 vs. 95.7% by pill counts and diaries</td>
<td>Delays (&gt;60 min) in taking medication occurred on 55.6% of total days recorded by MEMS</td>
</tr>
<tr>
<td>(Olivieri et al., 1991)</td>
<td>n = 7 patients (10-22 years) with transfusion dependent homozygous β thalassaemia</td>
<td>MEMS vs. pill counts and patient diaries</td>
<td>Mean adherence by MEMS was 88.7 vs. 95.7% by pill counts and diaries</td>
<td>Delayed in taking medication occurred on 55.6% of total days recorded by MEMS</td>
</tr>
</tbody>
</table>

(continued)
### Table III. Continued

<table>
<thead>
<tr>
<th>Reference</th>
<th>Sample/Regimen</th>
<th>Comparison</th>
<th>Results</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Apter, Tor, and Feldman, 2001)</td>
<td>MDI Monitors (MDILog/Nebulizer chronolog/doser)</td>
<td>Bench study, comparing three MDILog devices to diary record kept by investigators</td>
<td>Accuracy of MDILog for actuation of MDI = 97 to 100%; inhalation = 82 to 100%; shaking = 86 to 95%; late inhalations/multiple actuations = 97 to 99%</td>
<td>No artifactual recordings made by MDILogs during 3 days when carried in a bookbag; MDILog judged to be more accurate and reliable than previous versions</td>
</tr>
<tr>
<td>(Julius, Sherman, &amp; Hendeles, 2002)</td>
<td>MDI (1, 2, and 4 puffs of fluticasone propionate)</td>
<td>Bench study of accuracy: three different electronic monitors (Doser CT, MDILog, and SmartMist) actuated twice daily for 30 days with 2 units of each device and compared to date and time of actuation recorded in a log by investigators</td>
<td>Accuracy mean (± SD): 100% for SmartMist; 94.3 ± 2.9% for Doser CT; 90.1 ± 6.9% for MDILog; there were no significant differences in accuracy between dosing schedules for any device</td>
<td>Additional actuations recorded by Doser CT and MDILog, with trend for decreasing accuracy over time (possibly due to battery decay); Doser CT does not record time of each actuation &amp; data can not be downloaded to a computer; MDILog errors were “multiple dosing errors” (when an actuation is within 6–8 seconds of previous actuation)</td>
</tr>
<tr>
<td>(Bender, Milgrom, Rand, &amp; Ackerson, 1998)</td>
<td>$n = 24$ children (6–12 years) with asthma/inhaled β-agonists and steroids</td>
<td>Metered-dose inhaler chronolog (MDIC) compared to patient diaries</td>
<td>Complete use of corticosteroids recorded on a median of 4.9% of days by MDIC vs. 54% by patient report; complete use of β-agonists 12.7 by MDIC vs. 30% by patient report</td>
<td>Self-report distortion was correlated with lower parent education and affective responsiveness in family</td>
</tr>
<tr>
<td>(Bender, Milgrom, Rand, &amp; Ackerson, 2000)</td>
<td>$n = 27$ children (7–12 years) with asthma/inhaled steroid</td>
<td>Parent and child self-report vs. canister weighing vs. Doser CT</td>
<td>Mean adherence for parent and child report over 80%, for canister weighing = 69%, for Doser CT = 50%</td>
<td>Of the 301 Doser CT devices used in the study, 21% failed such that no data could be retrieved</td>
</tr>
<tr>
<td>(Butz, Donithan, Bollinger, Rand, &amp; Thompson, 2005)</td>
<td>$n = 157$ children with asthma (2–8 years old)</td>
<td>Nebulizer monitor (Hill Rom, Inc.) vs. asthma diary cards</td>
<td>Concordance between diary and nebulizer monitor data was 85% agreement for use and nonuse</td>
<td>12 nebulizer monitor failures (8%). Over four periods of time, return rates for diary data decreased from 75 to 44% compared to 92% usable Nebulizer monitor data</td>
</tr>
<tr>
<td>(Gibson, Ferguson, Aitchison &amp; Paton, 1995)</td>
<td>$n = 29$ children with asthma (15 months to 5 years) on prophylactic MDI</td>
<td>Nebulizer chronolog (NC300) compared to parent diaries</td>
<td>Mean daily adherence ($n = 22$) was 48% by NC300 vs. 72% by parent report</td>
<td>Significant drop (7%) in adherence during the last 20 days of study vs. first 20 days</td>
</tr>
<tr>
<td>(Chemlik &amp; Doughty, 1994)</td>
<td>$n = 20$ children &amp; adults (11–72 years) with asthma/inhaled steroids and peak flow monitoring</td>
<td>Nebulizer chronolog (inhaled steroids) and Wright Mini-Log (peak flow) vs. patient diaries</td>
<td>52.5% error rate (deviation of 10% in actual/phantom readings) with diaries vs. Nebulizer chronolog 17.5% error rate with diaries vs. Wright Mini-Log</td>
<td>73% of diary recording errors on inhaler use were over-reporting of medication intake</td>
</tr>
</tbody>
</table>

(continued)
Phone Diary ($r$’s = .88–.94) (Modi & Quittner, 2006b) and provides more accurate estimates of “true compliance” compared to traditional nebulizer monitors (Convway et al., 2002).

**Discussion**

Eighteen measures of adherence for pediatric chronic conditions were reviewed. A significant strength of this area is the diversity of methods that have been developed to measure these complex behaviors, including self-report/structured interviews, daily diary procedures, and electronic monitoring. This systematic review provided an interesting perspective on the current state of pediatric adherence research and suggested several important directions for the future. First, there were surprisingly few self-report and interview measures in the published literature. Most likely there are other self-report and interview measures that are being used, but have not yet accrued sufficient psychometric data for publication. Only 11 measures were found, with four meeting the criteria for “well-established.” Three measures were in the “approaching well-established” and four were in the “promising” category. Second, several major pediatric chronic conditions, such as juvenile rheumatoid arthritis (JRA), sickle cell anemia, and epilepsy were not covered by any of the existing self-report or interview measures. One reason for this may be the skepticism with which self-report measures are viewed, given their consistent over-reporting of adherence behaviors (Quittner et al., 2000b; Rapoff, 1999). Examination of the psychometric evidence supporting these measures in Table I indicates good agreement between parents and children, but overestimates of adherence in comparison to diary and electronic monitoring.

What are the alternatives to traditional self-report or interview-based measures of adherence? One possibility is to use daily diary procedures which are, in fact, a form of self-report. However, this method of self-report is structured to reduce the memory and social desirability biases associated with paper–pencil measures. Both of the diary measures included in this review were rated as
“well-established” and are being applied to a variety of chronic illness populations. Evidence of their convergence with other, more “objective” electronic monitors provides strong support for their validity in comparison to self-report questionnaires and interviews.

This shift toward “real time” assessment and the development of measures that capture daily activities and functioning can be seen in other areas of psychology, in which ecological momentary assessment (also called experience sampling) and day reconstruction methods are being applied (Csikszentmihalyi & Larson, 1987; Kahneman et al., 2004). Experience sampling methods have used electronic pagers to elicit affect and arousal during daily activities (Csikszentmihalyi & LeFevre, 1989). Schiffman and colleagues (2002) have used hand-held computers (PDAs) to record the use of cigarettes and antecedents of smoking behaviors, and preprogrammed wristwatches have been used to assess mood, pain and disability in patients with arthritis (Stone, Broderick, Porter, & Kaell, 1997). These methods often provide rich, sequential information about behavior and affect, which can increase our understanding of the processes that influence complex behaviors, such as adherence (Modi & Quittner, 2006b).

As electronic microchip technologies have advanced, their utility for measuring adherence has improved. Earlier devices that recorded MDI adherence were simplistic and provided minimal information. In contrast, newer generations and prototypes of the MDILog are more reliable and have added important features to assess the techniques patients use when taking their medication (e.g., shaking before inhaling). These devices, however, still assume that when the device is actuated, the medication is being taken by the patient. Electronic monitors have a number of other limitations, including malfunctions, battery failures, complex software that must be learned, and a high cost. Although they do provide more reliable and accurate data than other measures when they are working properly, managing these monitors requires technical expertise and a significant commitment of time and resources.

Although some consider electronic monitors the “gold standard” against which all other measures of adherence should be compared, data presented in this review do not support that position. Studies that used electronic monitors reported significant amounts of missing data, numerous device failures, the loss of monitors, and problems downloading data. Importantly, they are not available for all components of treatment (e.g., dietary alterations). It is also clear that most electronic monitors are not currently feasible for clinical use (blood glucose monitors are the exception), and thus their utility is limited to the research context. Improved technology and reduced cost will be required before electronic monitors can become the “gold standard.”

**Recommendations**

This review indicates that we have made substantial progress in the last decade in developing reliable and valid measures of adherence for pediatric populations. The methods of assessment in this area are among the most innovative in our field, and we now have an opportunity to “triangulate” two or more methods to obtain a more accurate assessment of adherence behaviors. This review also indicates that this area is in its infancy compared to assessment tools in other child specialties (e.g., academic achievement, child behavior problems), with additional research needed. The following is a list of recommendations that may help guide future instrument development and research on the assessment of adherence:

(a) Our review indicates that electronic monitors have not yet achieved the status of the “gold standard, and thus we suggest that studies of adherence include at least two methods of assessment (e.g., diary plus electronic monitoring). This increases the complexity of the analyses (see next recommendation), but will enable researchers to examine the extent of convergence across two different methods and potentially triangulate the data to obtain a more reliable result. This may not be feasible in clinical settings, in which both time and technical expertise may be lacking. However, for some chronic conditions, such as diabetes, blood glucose monitors are routinely downloaded as part of the clinic visit. As other types of monitors become more user-friendly and less expensive, they could also become part of standard care [e.g., e-Flow rapid® (Pari GmbH, München, Germany), for nebulized medications], facilitating a discussion of adherence with the patient and family. Unfortunately, in many subspecialty clinics, a “don’t ask, don’t tell” policy prevails and members of the health care team are often reluctant to ask patients and family members whether they are able to successfully manage their treatments.

(b) One of the methodological challenges of measuring adherence is the variation in rates of adherence related assessment method. As mentioned above, we recommend that a minimum of two measures be used—which increases the complexity of the data analysis. If rates of adherence differ (which is likely across self-report, diary, and electronic methods), which rate of adherence should be reported? How should data from different measures be
treatments. However, the reasons patients and families find it difficult to comply with their treatment is clear from studies of adherence over the past 20 years that take into account the ‘deficit’ model to identify culture-specific factors that are related to poor adherence. Another suggestion is to utilize newer modeling techniques, such as hierarchical linear modeling, which allows data from several measures to be combined to form an underlying construct (frequency of taking oral medications), with measurement error from each source defined and reduced in the modeling process (McCullagh & Nelder, 1989).

(c) The identification of barriers to adherence is a new and promising direction for measurement development. It is clear from studies of adherence over the past 20 years that patients and families find it difficult to comply with their treatments. However, the reasons for poor adherence are less well-understood and have only recently been measured (Modi & Quittner, 2006a). Three instruments assessing barriers to adherence were identified during this review, but were not included because they measure factors that impede adherence, rather than measuring adherence rates (Logan, Zelikovsky, Labay, & Spergel, 2003; Modi & Quittner, 2006a; Riekert & Drotar, 2002). We strongly recommend that studies of adherence include an assessment of the barriers that patients and families encounter. Identifying individual and family-level reasons for poor adherence will be critical as the field moves toward the development and evaluation of interventions to improve adherence behaviors.

(d) Another area that should be addressed is whether patients and families have the appropriate knowledge and skills to perform the treatments correctly. Although knowledge of the disease per se has not been strongly associated with rates of adherence, it is likely that treatment-specific knowledge (e.g., when and how to perform various treatments) is associated with adherence. For example, research in CF shows that parents and children have a number of misconceptions about when and how to do their treatments (e.g., taking enzymes before or after meals) which affect adherence and the efficacy of the treatment (Henley & Hill, 1990; Modi & Quittner, 2006a). Having the skills to perform the treatment is also an important issue which is rarely addressed. For example, most patients with asthma do not know how to use a metered dose inhaler correctly (Burkhart, Rayens, & Bowman, 2005). Although they are not direct measures of adherence, measures of knowledge and skills can provide critical information for an adherence intervention. If children are spending the time to take their medications, we need to make sure they have the knowledge and skills to gain the maximum benefit. This is even more important as children get older and begin to assume responsibility for their treatments, or encounter changes in their treatments with advancing age (e.g., nebulizer face mask vs. mouthpiece).

(e) In conjunction with the development of skills tests, we strongly recommend that comprehensive treatment plans be developed and utilized in clinics treating children with chronic conditions. These ‘treatment plans’ are necessary for two reasons: First, medical regimens typically include multiple components (e.g., medications plus dietary alterations) with different dosages, time schedules and durations. This makes it extremely difficult for families to be adherent without having something in writing they can refer to. Second, medical charts often do not have complete information on treatment recommendations (e.g., duration and frequency of treatment) or on recent changes in the prescription, and thus it is difficult to determine what the family understands and is adhering to (i.e., the denominator in the adherence equation). As more hospitals and clinics move to electronic charts, this may provide an opportunity to record and provide written treatment plans to families.

(f) There is little data on how racial and ethnic differences in attitudes, beliefs and behaviors affect adherence to chronic therapies. Often studies of pediatric adherence do not have samples that are sufficiently large and representative to permit analyses of subgroups according to race and ethnicity; however, validation studies often do include minority samples. Data on these differences have been reported for African-American versus Non-Hispanic White families of children receiving kidney transplants (Tucker et al., 2002) and African-American, Hispanic, and Non-Hispanic White children and teens with CF (Quittner, Schechter, Rasouliyan, Pasta, & Wagener, 2006). However, more research is needed on this important topic. Tucker and colleagues (2002) presented a “cultural difference” rather than “deficit” model to identify culture-specific factors that are associated with treatment adherence. This model could be useful in a variety of pediatric chronic conditions and would likely have implications for intervention as well as assessment.
We recommend that more refined EBA classifications be developed to better capture the measurement characteristics of adherence behaviors. Given that multiple methods are used in this area, it is not always possible to evaluate them with traditional psychometric parameters. Furthermore, finer distinctions between the categories in terms of reliability and validity would be beneficial (Mash & Hunsley, 2005).

In sum, improving adherence in children and adolescents with chronic illnesses is going to be the key to better healthcare delivery and health outcomes over the next 20 years. In order to address the complex issues related to adherence behaviors, reliable, ecologically valid, and empirically supported measures of adherence will be required. This systematic review highlights a number of well-established measures and methods that can be used for pediatric populations; however, further measurement development is necessary to advance the field.

Conflicts of interest: None declared.

Appendix A

Self-Care Adherence Interview (SCAI)

Central Reference

Purpose of Measure
The SCAI is a 15-item semi-structured interview for youth and their parents assessing adherence to the diabetes regimen.

Address for Manual and Measure
The SCAI can be requested from Dr Cindy L. Hanson at University of Central Florida, Department of Psychology, Orlando, FL32816, USA.

Self-Care Inventory (SCI)

Central Reference

Purpose of Measure
The SCI is a measure of self-reported adherence to the diabetes regimen over a 1-month period of time.

Diabetes Regimen Adherence Questionnaire (DRAQ)

Central Reference

Purpose of Measure
The DRAQ is a retrospective self-report measure of diabetes adherence.

Address for Manual and Measure
The DRAQ was developed by Dr Martha Brownlee-Duffeck and can be obtained from her at Martha.Brownlee-Duffeck@med.VA.gov.

Behavioral Affective and Somatic Experiences Scale (BASES)—Compliance Scale (Parent Version)

Central Reference

Purpose of Measure
The BASES measure was designed to assess the behavioral, affective, and somatic outcomes in the acute phase of bone marrow transplantation and includes a “Compliance” scale.

Address for Manual and Measure
The behavioral affective and somatic experiences scale was developed by Dr Sean Phipps and can be obtained from him at sean.phipps@stjude.org.

The Self-regulation of Medication Adherence Battery (SRMAAB)

Central Reference
Tucker, C. M., Petersen, S., Herman, K. C., Fennell, R. S., Bowling, B., Pedersen, T., & Josmik, J. R. (2001). Self-regulation predictors of medication adherence among ethnically different pediatric patients with...

**Purpose of Measure**  
The SRMAAB is a verbally administered adherence questionnaire for pediatric renal transplant patients, which assesses adherence motivation, perceived control of medication adherence, and perceived caregiver support of medication adherence.

**Address for Manual and Measure**  
Dr. Carolyn M. Tucker, Department of Psychology, P.O. Box 112250 University of Florida, Gainesville, FL 32611, USA. E-mail: cmtucker@ufl.edu

**Disease Management Interview (Formerly Known as the Treatment Adherence Questionnaire-CF)**  
**Central Reference**  

**Purpose of Measure**  
The DMI-CF is an interview-based self-report measure of treatment adherence for patients with CF. It is used for children of 10 years of age and older and their parents. This has been adapted to children and parents of children with asthma.

**Address for Manual and Measure**  
The DMI-CF is available from Dr Alexandra Quittner at aqquittner@miami.edu. The DMI-Diabetes version is available from Dr Suzanne Bennett Johnson at suzanne.johnson@med.fsu.edu.

**Treatment Adherence Rating Scale (TARS)**  
**Central Reference**  

**Purpose of Measure**  
The TARS is a self-report measure of treatment adherence for patients with CF and their parents.

**Address for Manual and Measure**  
The TARS is available in the original citation listed above.

**Family Asthma Management System Scale (FAMSS)**  
**Central Reference**  

**Purpose of Measure**  
The FAMSS is a semi-structured interview for caregivers (school-aged children can be included as an additional informant) designed to assess the management of children’s asthma within the context of the family.

**Address for Manual and Measure**  
The FAMSS was originally developed by Dr Mary D. Klinnert. Correspondence should be addressed to Mary Klinnert, PhD, National Jewish Center for Immunology and Respiratory Medicine, 1400 Jackson St, Denver, CO 80206, USA.

**Disease Management Interview-Asthma Version**  
**Central Reference**  

**Purpose of Measure**  
The DMI-Asthma is an interview-based self-report measure of treatment adherence for patients with asthma. It is used for children of 10 years of age and older and their parents.

**Address for Manual and Measure**  
The DMI-Asthma is available from Dr Avani Modi at avani.modi@cchmc.org.

**Pediatric AIDS Clinical Trials Group (PACTG): Adherence Modules**  
**Central Reference**  

**Purpose of Measure**  
The PACTG is an interview-administered measure that is conducted with primary caregivers and it consists of two adherence modules. Module One assesses adherence to the HIV HAART regimen and Module Two assesses barriers to adherence.
Address for Manual and Measure
The PACTG is available at www.fstrf.org/qol/peds/pedadhere.html

Parent-Report of Medical Adherence in Spina Bifida Scale (PROMASB)

Central Reference

Purpose of Measure
The PROMASB is a Likert scale parent-report measure of adherence for spina bifida and includes treatment aspects such as catheterization, bowel care, skin care, medication, and ambulation.

Address for Manual and Measure
The PROMASB can be obtained in the appendix of the original citation.

24 Hr Recall—Diabetes

Central Reference

Purpose of Measure
The 24 hr recall interview was designed to assess adherence behaviors in childhood diabetes. Respondents were asked to recall the previous day’s events and within interview, 13 measures of adherence are obtained; injection regularity, injection interval, injection–meal timing, regularity of injection–meal timing, calories consumed, percentage of calories from fat, percentage of calories from carbohydrates, concentrated sweets, eating frequency, exercise frequency and duration, exercise type, and glucose testing frequency.

Address for Manual and Measure
The diabetes management interview was developed by Dr Suzanne Bennett Johnson and can be obtained upon request (E-mail: suzanne.johnson@med.fsu.edu).

Daily Phone Diary (DPD)

Central Reference

Purpose of Measure
The DPD uses a cued recall procedure to track parents and/or older children/adolescents through their activities over the past 24 hr. For all activities lasting 5 min or longer, participants report the type of activity, duration, and who was present. Each activity, including medications and treatments, is recorded by the interviewer on a computer screen with clock hands which rotate through a 24 hr clock, a set of activities, companions, and a rating scale for mood.

Address for Manual and Measure
The DPD was developed by Dr. Alexandra L. Quittner and can be obtained upon request (E-mail: aquittner@miami.edu).

Medication Event Monitoring System (MEMS)

Purpose of Measure
The MEMS cap is an electronic monitor embedded within a cap that fits on pill vial containers and records and stores information on the date and time the vial was opened.

Address for Monitors
APREX (division of AARDEX), 2849B Whipple Road, Union City, CA 94587. Phone: 877-227-3391; Fax: 510-476-1946; Website: www.aardex.ch.

MDI monitors (MDILog)

Purpose of Measure
This is an electronic device that attaches to a metered dose inhaler (MDI) and records the date and time of inhaled medication use, including whether the inhaler was shaken(to mix the medication in the canister), dispensed, and the aerosolized medication was inhaled.

Address for Monitors

Halolite™

Purpose of Measure
The Halolite™ is an electronic device that records the date, time, and length of nebulized treatments (e.g., bronchodilators, inhaled antibiotics).
Address for Monitors
AAD devices are available from Profile Therapeutics, UK.

Received November 15, 2006; revisions received July 12, 2007; accepted July 12, 2007

References


